Status:
COMPLETED
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Swiss National Science Foundation
Goldschmidt-Jacobson Foundation
Conditions:
Sexual Functioning
Eligibility:
MALE
18-50 years
Phase:
PHASE2
Brief Summary
This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy men.
Detailed Description
This placebo-controlled, double-blind crossover study is to evaluate the GLP-1 analogue dulaglutide regarding changes in sexuality, the mood and the reproductive axis in healthy men. The study consis...
Eligibility Criteria
Inclusion
- Healthy men with normal weight (BMI 18.5-25kg/m2 or BMI 25.1-30kg/m2 and waist circumference \<102cm)
- Written informed consent
- Active sex life (sex with partner or masturbation ≥2x/week)
- Satisfactory sex life
- No Hypogonadism (morning total testosterone ≥12mmol/l)
Exclusion
- History of pancreatitis
- History of psychiatric disease (by questioning the participant, also regarding current psychiatric treatment)
- Daily nicotine abuse
- Alcohol consumption (\>1 glass/day)
- Substance abuse (as eg cannabis, anabolic steroids, benzodiazepines, opiates, psychostimulants)
- Regular intake of medication at any time
Key Trial Info
Start Date :
May 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 5 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04687514
Start Date
May 5 2021
End Date
September 5 2022
Last Update
September 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Endocrinology, Diabetes and Metabolism
Basel, Switzerland, 4031